Department of Surgery, University of Texas Medical School, Houston, TX, USA.
Surgery. 2012 Nov;152(5):790-3. doi: 10.1016/j.surg.2012.06.006. Epub 2012 Jul 31.
Bone marrow-derived mesenchymal stromal cells (MSCs) used as "MSC therapy" after traumatic brain injury act as remote "bioreactors" via stimulation of lung macrophages and augmention of T regulatory cell production by the spleen, leading to systemic increases in circulating anti-inflammatory cytokines and alteration of the locoregional milieu of the central nervous system. The altered intracerebral microenvironment leads to modulation of the resident microglia population, thereby stimulating an increase in the ratio of M2 (anti-inflammatory) macrophage to M1 (proinflammatory) macrophage, and it is this effect that accounts for the observed neuroprotection.
骨髓间充质基质细胞（MSCs）在创伤性脑损伤后作为“MSC 治疗”，通过刺激肺巨噬细胞和增加脾脏中 T 调节细胞的产生，充当远程“生物反应器”，导致循环抗炎细胞因子的全身增加和中枢神经系统的局部环境改变。改变的脑内微环境导致驻留小胶质细胞群体的调节，从而刺激 M2（抗炎）巨噬细胞与 M1（促炎）巨噬细胞的比例增加，正是这种效应导致了观察到的神经保护作用。
